Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion type Assertion NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_head.
- NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion description "[High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_provenance.
- NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion evidence source_evidence_literature NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_provenance.
- NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion SIO_000772 20146086 NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_provenance.
- NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion wasDerivedFrom befree-20150227 NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_provenance.
- NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_assertion wasGeneratedBy ECO_0000203 NP531207.RAXLzz_2gCTXsH3gMQ53cOZT0fb7kI8Sn-l8swipt9Ces130_provenance.